Drug Trial Radar · NCT07152041
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 28, 2025
Primary completion
Dec 2029
Study completion Jun 2030
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 month, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed pediatric/adolescent patients with Ph+ ALL. The CCCG-Ph+ B-ALL-2025 protocol will be modified as following compared to the CCCG-ALL-2020 protocol
Conditions
- Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
- Childhood Leukemia, Acute Lymphoblastic
Interventions
olverembatinibDrug
All Ph+-ALL patients will uniformly use the 3rd generation of TKI olverembatinib (OVB) instead of dasatinib throughout the regimen. OVB is combined with Vincristine and Prednisone (VP) during the first 2 weeks and with blinatumomab during the last 4 weeks of remission induction in this protocol. Patients will receive blinatumomab for 28 days as induction instead of CAT to improve induction response and avoid toxicity. All patients will receive two cycles of HDMTX+Blina-14 and 4 times of triple intrathecal therapy (TIT) throughout the consolidation 1 phase. To decrease the toxicities of high-dose AraC, the dosage will be reduced to 1 g/m2 in the consolidation 2 phase in contrast to 2 g/m2 in 2020 protocol. Throughout the early Maintenance Therapy, dexamethasone and vincristine combination will be added with either venetoclax or daunorubicin alternatively for five cycles, given after MTX and 6-MP.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Day 48 end-of-induction measurable residual diseases (MRD48) after induction remission with olverembatinib and blinatumomab, compared to MRD46 of those treated with dasatinib plus chemotherapy induction (CCCG-ALL-2015 /2020) or from historical cohorts .Time frame: Up to approximately 4.5 years.
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Anhui Medical University Second Affiliated Hospita
Hefei, Anhui, China · Not yet recruiting
Chongqing Medical University Affiliated Children's Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Not yet recruiting
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China · Not yet recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Wuhan Children's Hospital
Wuhan, Hubei, China · Not yet recruiting
Hunan Children's Hospital
Changsha, Hunan, China · Not yet recruiting
The Third Xiangya Hospital of the Central South University
Changsha, Hunan, China · Not yet recruiting
Nanjing Children's Hospital Affiliated to Nanjing Medical University
Nanjin, Jiangsu, China · Not yet recruiting
Children's Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
Jiangxi Provincial Children's Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Not yet recruiting
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Not yet recruiting
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanghai Children's Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shenzhen Children's Hospital
Shenzhen, Shenzhen, China · Not yet recruiting
West China Second University Hospita
Chengdu, Sichuan, China · Not yet recruiting
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality, China · Recruiting
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality, China · Not yet recruiting
Hong Kong Children's Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.